MA61557B1 - Composés et compositions servant d'inhibiteurs de sppl2a - Google Patents
Composés et compositions servant d'inhibiteurs de sppl2aInfo
- Publication number
- MA61557B1 MA61557B1 MA61557A MA61557A MA61557B1 MA 61557 B1 MA61557 B1 MA 61557B1 MA 61557 A MA61557 A MA 61557A MA 61557 A MA61557 A MA 61557A MA 61557 B1 MA61557 B1 MA 61557B1
- Authority
- MA
- Morocco
- Prior art keywords
- inhibitors
- sppl2a
- compositions
- compounds
- peptidase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des composés tricycliques comprenant une fraction diazépinone qui sont efficaces pour inhiber Sppl2a (peptidase 2a de type peptidase de peptide signal), des compositions pharmaceutiques contenant de tels inhibiteurs, et des procédés d'utilisation de tels inhibiteurs et de telles compositions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063079604P | 2020-09-17 | 2020-09-17 | |
| EP21773886.3A EP4214210B1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
| PCT/IB2021/058398 WO2022058902A1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA61557B1 true MA61557B1 (fr) | 2025-05-30 |
Family
ID=77897680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA61557A MA61557B1 (fr) | 2020-09-17 | 2021-09-15 | Composés et compositions servant d'inhibiteurs de sppl2a |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20230365571A1 (fr) |
| EP (2) | EP4214210B1 (fr) |
| JP (2) | JP7771172B2 (fr) |
| KR (1) | KR20230069947A (fr) |
| AU (1) | AU2021342783A1 (fr) |
| CA (1) | CA3192763A1 (fr) |
| CL (2) | CL2023000728A1 (fr) |
| CO (1) | CO2023004646A2 (fr) |
| CR (1) | CR20230142A (fr) |
| DK (1) | DK4214210T3 (fr) |
| DO (1) | DOP2023000055A (fr) |
| EC (1) | ECSP23027092A (fr) |
| ES (1) | ES3028668T3 (fr) |
| FI (1) | FI4214210T3 (fr) |
| GE (2) | GEP20257771B (fr) |
| HR (1) | HRP20250562T1 (fr) |
| HU (1) | HUE071569T2 (fr) |
| IL (1) | IL300953B1 (fr) |
| JO (1) | JOP20230044A1 (fr) |
| LT (1) | LT4214210T (fr) |
| MA (1) | MA61557B1 (fr) |
| MD (1) | MD4214210T2 (fr) |
| MX (1) | MX2023003122A (fr) |
| PE (1) | PE20231099A1 (fr) |
| PL (1) | PL4214210T3 (fr) |
| PT (1) | PT4214210T (fr) |
| RS (1) | RS66874B1 (fr) |
| SI (1) | SI4214210T1 (fr) |
| SM (1) | SMT202500216T1 (fr) |
| WO (1) | WO2022058902A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116947813A (zh) * | 2023-07-06 | 2023-10-27 | 绍兴贝斯美化工股份有限公司 | 一种3-氯-4-氨基-1-(3-吡啶基)-1h-吡唑的制备方法 |
| WO2025175102A1 (fr) | 2024-02-15 | 2025-08-21 | Incyte Corporation | Inhibiteurs de sppl2a |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2124503C1 (ru) * | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| GB9612622D0 (en) | 1996-06-17 | 1996-08-21 | Zeneca Ltd | Chemical process |
| US6432944B1 (en) * | 2000-07-06 | 2002-08-13 | Bristol-Myers Squibb Company | Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| CA2573644A1 (fr) * | 2004-07-12 | 2006-02-16 | Idun Pharmaceuticals, Inc. | Analogues de tetrapeptide |
| US7989441B2 (en) * | 2005-06-08 | 2011-08-02 | Novartis Ag | Organic compounds |
| WO2015160772A1 (fr) | 2014-04-15 | 2015-10-22 | Janssen Pharmaceutica Nv | Modulateurs tétrahydro-benzoimidazolyles de tgr5 |
-
2021
- 2021-09-15 GE GEAP202116217A patent/GEP20257771B/en unknown
- 2021-09-15 JP JP2023517751A patent/JP7771172B2/ja active Active
- 2021-09-15 PL PL21773886.3T patent/PL4214210T3/pl unknown
- 2021-09-15 SM SM20250216T patent/SMT202500216T1/it unknown
- 2021-09-15 ES ES21773886T patent/ES3028668T3/es active Active
- 2021-09-15 EP EP21773886.3A patent/EP4214210B1/fr active Active
- 2021-09-15 PT PT217738863T patent/PT4214210T/pt unknown
- 2021-09-15 DK DK21773886.3T patent/DK4214210T3/da active
- 2021-09-15 AU AU2021342783A patent/AU2021342783A1/en active Pending
- 2021-09-15 US US18/044,455 patent/US20230365571A1/en active Pending
- 2021-09-15 GE GEAP202516217A patent/GEAP202516217A/en unknown
- 2021-09-15 KR KR1020237011546A patent/KR20230069947A/ko active Pending
- 2021-09-15 EP EP25163259.2A patent/EP4578451A3/fr active Pending
- 2021-09-15 HU HUE21773886A patent/HUE071569T2/hu unknown
- 2021-09-15 MA MA61557A patent/MA61557B1/fr unknown
- 2021-09-15 SI SI202130298T patent/SI4214210T1/sl unknown
- 2021-09-15 CR CR20230142A patent/CR20230142A/es unknown
- 2021-09-15 IL IL300953A patent/IL300953B1/en unknown
- 2021-09-15 HR HRP20250562TT patent/HRP20250562T1/hr unknown
- 2021-09-15 MX MX2023003122A patent/MX2023003122A/es unknown
- 2021-09-15 LT LTEPPCT/IB2021/058398T patent/LT4214210T/lt unknown
- 2021-09-15 WO PCT/IB2021/058398 patent/WO2022058902A1/fr not_active Ceased
- 2021-09-15 PE PE2023001167A patent/PE20231099A1/es unknown
- 2021-09-15 MD MDE20230725T patent/MD4214210T2/ro unknown
- 2021-09-15 CA CA3192763A patent/CA3192763A1/fr active Pending
- 2021-09-15 RS RS20250568A patent/RS66874B1/sr unknown
- 2021-09-15 FI FIEP21773886.3T patent/FI4214210T3/fi active
-
2023
- 2023-02-27 JO JOJO/P/2023/0044A patent/JOP20230044A1/ar unknown
- 2023-03-14 CL CL2023000728A patent/CL2023000728A1/es unknown
- 2023-03-16 DO DO2023000055A patent/DOP2023000055A/es unknown
- 2023-04-14 EC ECSENADI202327092A patent/ECSP23027092A/es unknown
- 2023-04-14 CO CONC2023/0004646A patent/CO2023004646A2/es unknown
-
2024
- 2024-04-29 CL CL2024001312A patent/CL2024001312A1/es unknown
-
2025
- 2025-11-05 JP JP2025186205A patent/JP2026041723A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA61557B1 (fr) | Composés et compositions servant d'inhibiteurs de sppl2a | |
| MA48772B1 (fr) | Inhibiteurs de kras g12c et leurs procédés d'utilisation | |
| MA62912A1 (fr) | Inhibition de la protéase 1 spécifique de l'ubiquitine (usp1) | |
| TNSN04159A1 (fr) | Synthese controlee de ziprasidone et compositions en contenant | |
| TNSN99001A1 (fr) | Indoles 2,3-substitues servant d'agents anti-inflammatoires et analgesiques | |
| MA44851A (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| MA40893A (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA29160B1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| MA31963B1 (fr) | Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation | |
| MA52492B1 (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| EA200501805A1 (ru) | Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN98182A1 (fr) | Agonistes de prostaglandines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA51204B1 (fr) | Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique | |
| EP1073465A4 (fr) | Compositions pour recepteurs inhibiteurs des lymphocytes t et utilisation de telles compositions | |
| TNSN08196A1 (fr) | Derives de pyrazine | |
| TNSN06210A1 (fr) | Nitro-oxydérivés de prostaglandines | |
| TN2009000204A1 (fr) | Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase | |
| TNSN06051A1 (fr) | Derives de piperazine pour le traitement d'infections par le hiv | |
| TNSN02015A1 (fr) | Composes nouveaux antagonistes de ppar, et compositions les contenant | |
| TNSN98140A1 (fr) | Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| DE69837324D1 (de) | Behandlung der multiplen sklerose durch einnahme von copolymer-1 | |
| MA29791B1 (fr) | Composes therapeutiques. | |
| TNSN04225A1 (fr) | Derives de benzoxazine en tant que modulateurs de 5-ht6 et utilisations de ceux-ci | |
| MA30331B1 (fr) | ANTICORPS à EFGL 7 ET LEURS PROCEDES D'UTILISATION |